Page 285 - 2021_04-Haematologica-web

Letters to the Editor
IMvdS data interpretation, manuscript writing; RP study design, data interpretation, manuscript writing; MMvdH-E study design,
data interpretation, manuscript writing.
References
1. te Winkel ML, Appel IM, Pieters R, van den Heuvel-Eibrink MM. Impaired dexamethasone-related increase of anticoagulants is associ- ated with the development of osteonecrosis in childhood acute lym- phoblastic leukemia. Haematologica. 2008;93(10):1570-1574.
2. te Winkel ML, Pieters R, Hop WCJ, et al. Prospective study on inci- dence, risk factors, and long-term outcome of osteonecrosis in pedi- atric acute lymphoblastic leukemia. J Clin Oncol. 2011;29(31):4143- 4150.
3. MattanoLA,SatherHN,TriggME,NachmanJB.Osteonecrosisasa complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol. 2000; 18(18):3262-3272.
4. Girard P, Auquier P, Barlogis V, et al. Symptomatic osteonecrosis in childhood leukaemia survivors: prevalence, risk factors and impact of quality of life in adulthood. Haematologica. 2013;98(7):1089-1097.
5. MattanoLA,DevidasM,NachmanJB,etal.Effectofalternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13(9):906-915.
6. ToftN,BirgensH,AbrahamssonJ,etal.ResultsofNOPHOALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018;32(3):606-615.
7. Kawedia JD, Kaste SC, Pei D, et al. Pharmacokinetic, pharmacody- namic, and pharmacogenetic determinants of osteonecrosis in chil- dren with acute lymphoblastic leukemia. Blood. 2011;117(8):2340- 2347; quiz 2556.
8. Pieters R, Hunger SP, Boos J, et al. L-asp treatment in ALL: a focus on erwinia. Cancer. 2011;117(2):238-249.
9. Schmiegelow K, Attarbaschi A, Barzilai S, et al. Consensus defini- tions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016;17(6):e231-e239.
10. Karol SE, Janke LJ, Panetta JC, et al. Asparaginase combined with dis- continuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. PLoS One. 2019;14(5):e0216328.
11. Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexam- ethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol. 2008;26(12):1932-1939.
12.Finch ER, Smith CA, Yang W, et al. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;(Aug 2019):1-10.
13. Liu C, Janke LJ, Kawedia JD, et al. Asparaginase potentiates glucocor- ticoid-induced osteonecrosis in a mouse model. PLoS One. 2016;11(3):1-13.
14. Pieters R, de Groot-kruseman H, Van Der Velden V, et al. Successful therapy reduction and intensification for childhood acute lym- phoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34(22):2591-2601.
15. Toft N, Birgens H, Abrahamsson J, et al. Toxicity profile and treat- ment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia. Eur J Haematol. 2016;96(2):160-169.
16. Möricke A, Zimmermann M, Valsecchi MG, et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood. 2016;127(17):2101- 2112.
17.Mogensen SS, Harila-Saari A, Makitie O, et al. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65(10):e27300.
haematologica | 2021; 106(4)
1201